Format

Send to

Choose Destination
J Infect Chemother. 2019 May 18. pii: S1341-321X(19)30128-X. doi: 10.1016/j.jiac.2019.04.019. [Epub ahead of print]

The efficacy and safety of sitafloxacin and garenoxacin for the treatment of pneumonia in elderly patients: A randomized, multicenter, open-label trial.

Author information

1
Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. Electronic address: taiga-m@nagasaki-u.ac.jp.
2
Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
3
Japanese Red Cross Nagasaki Genbaku Hospital, 3-15 Mori-machi, Nagasaki, 852-8511, Japan.
4
Sasebo Chuo Hospital, 15 Yamato-cho, Sasebo 857-1195, Japan.
5
Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, 986-2 Keya, Tarami-cho, Isahaya, 859-0497, Japan.
6
Sasebo City General Hospital, 9-3 Hirase-cho, Sasebo, 857-0056, Japan.
7
Isahaya General Hospital, 24-1 Eishohigashi-cho, Isahaya, 854-8501, Japan.
8
Aino Memorial Hospital, 3838-1 Koh, Aino-cho, Unzen, 854-0301, Japan.
9
Ureshino Medical Center, 2436 Hei, Ureshino-cho, Ureshino, 843-0301, Japan.
10
Nagasaki Medical Center, 2-1001-1, Hisahara, Omura, 856-8562, Japan.
11
Hokusho Central Hospital, 299, Akasaka, Emukai-cho, Sasebo, 859-6131, Japan.
12
Izumikawa Hospital, 2405, Tei, Fukae-cho, Minamishimabara, 859-1504, Japan.

Abstract

Oral treatment for elderly outpatients with pneumonia is becoming increasingly important in this super-aged society from the perspective of cost-effectiveness and limited hospital capacities. We evaluated the efficacy and safety of two oral respiratory quinolones, sitafloxacin and garenoxacin, in elderly patients with pneumonia. This randomized, multicenter, open-label trial was conducted among patients aged ≥65 years with clinically and radiographically confirmed pneumonia in Japan. Patients were randomly assigned (1:1) to receive either sitafloxacin (100 mg/day) or garenoxacin (400 mg/day) for 3-10 days. The primary efficacy endpoint was the clinical cure rate at 5-10 days after the end of treatment. From December 2013 to November 2017, we enrolled 120 patients at 11 hospitals and randomly assigned 59 patients to the sitafloxacin group (1 patient withdrew) and 61 patients to the garenoxacin group. These included 30 patients with nursing and healthcare-associated pneumonia (NHCAP) (18 receiving sitafloxacin, 12 receiving garenoxacin) and 37 patients with aspiration pneumonia (16 receiving sitafloxacin, 21 receiving garenoxacin). The clinical cure rates in the sitafloxacin and garenoxacin groups were 88.5% (95% confidence interval: 76.6-95.6) and 88.9% (95% confidence interval: 77.4-95.8), respectively. No significant differences were observed in the incidence rates of drug-related adverse events between the sitafloxacin (20.7%; 12/58 patients) and garenoxacin (27.9%; 17/61 patients) groups. The most common adverse event was hepatic dysfunction, which occurred in seven patients in each group. We conclude that sitafloxacin and garenoxacin are comparably effective and safe for the treatment of pneumonia, including NHCAP and aspiration pneumonia, in elderly patients.

KEYWORDS:

Aspiration pneumonia; Community-acquired pneumonia; Garenoxacin; Nursing and healthcare-associated pneumonia; Sitafloxacin

PMID:
31113725
DOI:
10.1016/j.jiac.2019.04.019
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center